---
title: Media Coverage and Research Articles
layout: page
description: 'Read about Evusheld in the media.'
image: assets/images/media.png
nav-menu: true
---
This page contains media coverage, research articles, preprints, medical opinion pieces, and policy documents. If we are missing items, please email them to [the maintainer](mailto:martin@eve.gd).

## Media Coverage
These are articles in mainstream media/press releases, in reverse chronological order.

* Sharp, Christopher. ‘[Blood Cancer UK Says Government “Needs to Do More” amid Battle for Evusheld](https://www.express.co.uk/life-style/health/1629554/blood-cancer-uk-treatment-evusheld-covid)’. Express.co.uk, 26 June 2022.
* Evusheld for the UK. 2022. ‘[UK “Outlier” in Not Protecting 500,000+ Vulnerable Patients with New Lifesaving Drug. AstraZeneca Denies Government Claims of Further Testing](/assets/downloads/2022-06-21-Press-Release.pdf)’. 21 June 2022.
* Shapiro, Lindsey. 2022. ‘[Evusheld Boosts Antibodies Against COVID-19 in Vaccinated MS Patients](https://multiplesclerosisnewstoday.com/news-posts/2022/06/10/evusheld-boosts-antibodies-against-covid-19-vaccinated-ms-patients/)’. _Multiple Sclerosis News Today_ (blog). 10 June 2022.
* ‘[Evusheld Significantly Prevented COVID-19 Disease Progression or Death in Tackle Phase III Treatment Trial](https://www.zawya.com/en/press-release/companies-news/evusheld-significantly-prevented-covid-19-disease-progression-or-death-in-tackle-phase-iii-treatment-trial-appg120c)’. 2022. _Zawya_. 10 June 2022.
* ‘[AstraZeneca’s Evusheld Prevents Disease Progression in Phase III Covid-19 Trial](https://www.clinicaltrialsarena.com/news/astrazeneca-evusheld-covid-trial-2/)’. 2022. _Clinical Trials Arena_ (blog). 9 June 2022.
* AstraZeneca. 2022. ‘[Evusheld Significantly Prevented COVID-19 Disease Progression or Death in TACKLE Phase III Treatment Trial](https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-significantly-prevented-covid-19-disease-progression-or-death-in-tackle-phase-iii-treatment-trial.html)’. 8 June 2022.
* Chudleigh, Hannah. 2022. ‘[AstraZeneca’s Evusheld Successfully Prevents Progression to Severe COVID-19](https://www.biospace.com/article/astrazeneca-s-evusheld-successfully-prevents-progression-to-severe-covid-19-/)’. _BioSpace_. 8 June 2022.
* Kahn, Rachel. 2022. ‘[Evusheld – Does It Work against Omicron?](https://bloodcancer.org.uk/news/evusheld-does-it-work-against-omicron/)’ _Blood Cancer UK_. 6 June 2022.
* Sharp, Christopher. 2022. ‘[Covid: Why the Threat of the Virus Still Haunts Those Who Are Immunosuppressed](https://www.express.co.uk/life-style/health/1615894/covid-kidney-disease-immunosuppressed-exclusive/amp)’. Express, 29 May 2022.
* AstraZeneca. 2022. ‘[Evusheld Long-Acting Antibody Combination Retains Neutralising Activity against Omicron Variants BA.4 and BA.5, According to New Study from University of Oxford](https://www.astrazeneca.com/media-centre/medical-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-omicron-variants-ba4-ba5-according-new-study-university-oxford.html)’. 25 May 2022.
* Barnes, Oliver. 2022. ‘[UK Accused of Leaving Covid Immunocompromised “out to Dry”](https://www.ft.com/content/fe03bc3b-a381-462d-b373-87dabde0a9ab)’. _Financial Times_, 4 May 2022.
* Kollewe, Julia. 2022. ‘[AstraZeneca Boss Calls for UK to Provide New Covid-19 Medicine to the Vulnerable](https://www.theguardian.com/business/2022/apr/29/evusheld-covid-19-medicine-astrazeneca-immunosuppressed-vulnerable-uk)’. _The Guardian_, 29 April 2022, sec. Business.
* Ennals, Ethan. 2022. ‘[Covid 19: Vulnerable Patients Denied £800 Anti-Viral Jab Unless They Go Private](https://www.dailymail.co.uk/health/article-10746187/Covid-19-Vulnerable-patients-denied-800-anti-viral-jab-unless-private.html)’. Daily Mail. 23 April 2022.
* AstraZeneca. 2022. ‘[Evusheld Long-Acting Antibody Combination Retains Neutralising Activity against Omicron Variants Including BA.2 in New Independent Studies](https://www.astrazeneca.com/media-centre/medical-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variants-including-ba2-in-new-independent-studies.html)’. 21 March 2022.
* ‘[Evusheld Approved to Prevent COVID-19 in People Whose Immune Response Is Poor](https://www.gov.uk/government/news/evusheld-approved-to-prevent-covid-19-in-people-whose-immune-response-is-poor)’. 2022. GOV.UK. 17 March 2022.
* AstraZeneca. 2022. ‘[AstraZeneca’s Antibody Combination, Evusheld (Tixagevimab Co-Packaged with Cilgavimab) Authorised for Use in Great Britain for Pre-Exposure Prophylaxis (Prevention) of COVID-19](https://www.astrazeneca.com/media-centre/press-releases/2022/astrazenecas-antibody-combination-evusheld-authorised-for-use-in-great-britain-for-pre-exposure-prophylaxis-prevention-of-covid-19.html)’. 17 March 2022.
* ‘[Individuals with Immunodeficiency at High Risk of Mortality Following SARS-CoV-2 Infection](https://www.birmingham.ac.uk/news/latest/2022/01/covid-immunodeficiency-death-risk-infection.aspx)’. 2022. University of Birmingham. 31 January 2022.


## Research Articles, Preprints, Medical Opinion Pieces, and Policy Documents
These are formal research studies into the efficacy and dosage of Evusheld. These are arranged by alphabetical order of first author. We list here all articles (attempting a comprehensive literature review) rather than merely those with positive findings.

Articles marked [PREPRINT] have not necessarily been subject to [peer review](https://en.wikipedia.org/wiki/Peer_review).

* Benotmane, Ilies, Aurélie Velay, Gabriela Gautier Vargas, Jérôme Olagne, Olivier Thaunat, Samira Fafi-Kremer, and Sophie Caillard. ‘[Pre-Exposure Prophylaxis with 300 Mg Evusheld Elicits Limited Neutralizing Activity against the Omicron Variant](https://doi.org/10.1016/j.kint.2022.05.008)’. _Kidney International_, 24 May 2022, S0085-2538(22)00383-0.
* Benotmane, Ilies, Aurélie Velay, Gabriela Gautier Vargas, Jérôme Olagne, Augustin Obrecht, Noëlle Cognard, Francoise Heibel, et al. ‘[Breakthrough COVID-19 Cases despite Prophylaxis with 150 Mg of Tixagevimab and 150 Mg of Cilgavimab in Kidney Transplant Recipients](https://doi.org/10.1111/ajt.17121)’. _American Journal of Transplantation_. Accessed 23 June 2022.
* Boschi, Céline, Philippe Colson, Audrey Bancod, Valérie Moal, and Bernard La Scola. ‘[Omicron Variant Escapes Therapeutic Monoclonal Antibodies (MAbs) Including Recently Released Evusheld®, Contrary to 8 Prior Main Variant of Concern (VOC)](https://doi.org/10.1093/cid/ciac143)’. _Clinical Infectious Diseases_, 16 February 2022, ciac143.
* Bruel, Timothée, Jérôme Hadjadj, Piet Maes, Delphine Planas, Aymeric Seve, Isabelle Staropoli, Florence Guivel-Benhassine, et al. ‘[Serum Neutralization of SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 in Patients Receiving Monoclonal Antibodies](https://doi.org/10.1038/s41591-022-01792-5)’. _Nature Medicine_ 28, no. 6 (June 2022): 1297–1302.
* Chavda, Vivek P., Riddhi Prajapati, Disha Lathigara, Bhumi Nagar, Jay Kukadiya, Elrashdy M. Redwan, Vladimir N. Uversky, Mukesh N. Kher, and Rajvi Patel. ‘[Therapeutic Monoclonal Antibodies for COVID-19 Management: An Update](https://doi.org/10.1080/14712598.2022.2078160)’. _Expert Opinion on Biological Therapy_ 22, no. 6 (June 2022): 763–80.
* Conte, William L., and Lilian Golzarri-Arroyo. 2022. ‘[Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in Patients with Multiple Sclerosis on b-Cell Depleters](https://doi.org/10.1016/j.msard.2022.103905)’. _Multiple Sclerosis and Related Disorders_ 63 (July): 103905.
* Das, Nabarun Chandra, Pritha Chakraborty, Jagadeesh Bayry, and Suprabhat Mukherjee. ‘[In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein](https://doi.org/10.3389/fimmu.2021.782506)’. _Frontiers in Immunology_ 12 (2021): 782506.
* Dong, Jinhui, Seth J. Zost, Allison J. Greaney, Tyler N. Starr, Adam S. Dingens, Elaine C. Chen, Rita E. Chen, et al. ‘[Genetic and Structural Basis for SARS-CoV-2 Variant Neutralization by a Two-Antibody Cocktail](https://doi.org/10.1038/s41564-021-00972-2)’. _Nature Microbiology_ 6, no. 10 (October 2021): 1233–44.
* Fitzsimmons, William E. ‘[COVID-19 Vaccine Associated Transverse Myelitis-Evusheld as an Option When Vaccination Is Not Recommended Due to Severe Adverse Events](https://doi.org/10.1080/21645515.2022.2068338)’. Human Vaccines & Immunotherapeutics, 5 May 2022, 1–2.
* Hu, Ye-Fan, Jing-Chu Hu, Hin Chu, Thomas Yau, Bao-Zhong Zhang, and Jian-Dong Huang. ‘[In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron](https://doi.org/10.3390/v14020390)’. _Viruses_ 14, no. 2 (14 February 2022): 390.
* [PREPRINT] Jurdi, Ayman Al, Leela Morena, Mariesa Cote, Emily Bethea, Jamil Azzi, and Leonardo V. Riella. 2022. ‘[Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis Is Associated with Lower Breakthrough Infection Risk in Vaccinated Solid Organ Transplant Recipients during the Omicron Wave](https://doi.org/10.1101/2022.05.17.22274980)’. _medRxiv_.
* [PREPRINT] Karaba, Andrew H., Jake D. Kim, Teresa P.-Y. Chiang, Jennifer L. Alejo, Aura T. Abedon, Jonathan Mitchell, Amy Chang, et al. ‘[Omicron BA.1 and BA.2 Neutralizing Activity Following Pre-Exposure Prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated Solid Organ Transplant Recipients](https://doi.org/10.1101/2022.05.24.22275467)’. _MedRxiv: The Preprint Server for Health Sciences_, 26 May 2022, 2022.05.24.22275467.
* Keam, Susan J. ‘[Tixagevimab + Cilgavimab: First Approval](https://doi.org/10.1007/s40265-022-01731-1)’. _Drugs_, 21 June 2022.
* Kotton, Camille N. ‘[Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients](https://doi.org/10.7326/M22-1026)’. _Annals of Internal Medicine_, 12 April 2022.
* Levin, Myron J., Andrew Ustianowski, Stéphane De Wit, Odile Launay, Miles Avila, Alison Templeton, Yuan Yuan, et al. ‘[Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19](https://doi.org/10.1056/NEJMoa2116620)’. The _New England Journal of Medicine_ 386, no. 23 (9 June 2022): 2188–2200.
* Mahase, Elisabeth. ‘[Covid-19: AstraZeneca Says Its Antibody Drug AZD7442 Is Effective for Preventing and Reducing Severe Illness](https://doi.org/10.1136/bmj.n2860)’. _BMJ (Clinical Research Ed.)_ 375 (19 November 2021): n2860.
* NHS England RAPID-C19. 2022. ‘[Defining the Highest-Risk Clinical Subgroups upon Community Infection with SARS-CoV-2 When Considering the Use of Neutralising Monoclonal Antibodies (NMABs) and Antiviral Drugs: Independent Advisory Group Report](https://www.gov.uk/government/publications/higher-risk-patients-eligible-for-covid-19-treatments-independent-advisory-group-report/defining-the-highest-risk-clinical-subgroups-upon-community-infection-with-sars-cov-2-when-considering-the-use-of-neutralising-monoclonal-antibodies)’. _GOV.UK_. 30 May 2022.
* Shaikh, Suhail A., Faiza Morado, Pnada Kawewat-Ho, Rachel Cartus, Roland Davoudi, Kevin Forrester, Krist Azizian, Emily Blodget, Thin Thin Maw, and Neha Nanda. ‘[Tixagevimab-Cilgavimab: Utilization in the Solid Organ Transplant Population](https://doi.org/10.1111/ctr.14661)’. _Clinical Transplantation_ 36, no. 6 (June 2022): e14661.
* Shields, Adrian M, Ariharan Anantharachagan, Gururaj Arumugakani, Kenneth Baker, Sameer Bahal, Helen Baxendale, William Bermingham, et al. 2022. ‘[Outcomes Following SARS-CoV-2 Infection in Patients with Primary and Secondary Immunodeficiency in the UK](https://doi.org/10.1093/cei/uxac008)’. _Clinical and Experimental Immunology_, January, uxac008.
* Stuver, Robert, Gunjan L. Shah, Neha S. Korde, Lindsey E. Roeker, Anthony R. Mato, Connie L. Batlevi, David J. Chung, et al. 2022. ‘[Activity of AZD7442 (Tixagevimab-Cilgavimab) against Omicron SARS-CoV-2 in Patients with Hematologic Malignancies](https://doi.org/10.1016/j.ccell.2022.05.007)’. _Cancer Cell_, May.
* Montgomery, Hugh, F. D. Richard Hobbs, Francisco Padilla, Douglas Arbetter, Alison Templeton, Seth Seegobin, Kenneth Kim, et al. 2022. ‘[Efficacy and Safety of Intramuscular Administration of Tixagevimab–Cilgavimab for Early Outpatient Treatment of COVID-19 (TACKLE): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial](https://doi.org/10.1016/S2213-2600(22)00180-1)’. _The Lancet Respiratory Medicine_.
* Tada, Takuya, Hao Zhou, Belinda M. Dcosta, Marie I. Samanovic, Vidya Chivukula, Ramin S. Herati, Stevan R. Hubbard, Mark J. Mulligan, and Nathaniel R. Landau. ‘[Increased Resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies](https://doi.org/10.1016/j.ebiom.2022.103944)’. _EBioMedicine_ 78 (April 2022): 103944.
* Touret, Franck, Cécile Baronti, Hawa Sophia Bouzidi, and Xavier de Lamballerie. ‘[In Vitro Evaluation of Therapeutic Antibodies against a SARS-CoV-2 Omicron B.1.1.529 Isolate](https://doi.org/10.1038/s41598-022-08559-5)’. _Scientific Reports_ 12, no. 1 (18 March 2022): 4683.
* [PREPRINT] Tuekprakhon, Aekkachai, Jiandong Huo, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, Daming Zhou, Helen M. Ginn, Muneeswaran Selvaraj, et al. 2022. ‘[Further Antibody Escape by Omicron BA.4 and BA.5 from Vaccine and BA.1 Serum](https://doi.org/10.1101/2022.05.21.492554)’. _bioRxiv_.
* Willicombe, Michelle, Miranda Scanlon, Fiona Loud, and Liz Lightstone. 2022. ‘[Should We Be Clinically Assessing Antibody Responses to Covid Vaccines in Immunocompromised People?](https://doi.org/10.1136/bmj.o966)’ BMJ 377 (April): o966.
* Wise, Jacqui. ‘[Covid-19: Evusheld Is Approved in UK for Prophylaxis in Immunocompromised People](https://doi.org/10.1136/bmj.o722)’. _BMJ (Clinical Research Ed.)_ 376 (17 March 2022): o722.
* Yamasoba, Daichi, Yusuke Kosugi, Izumi Kimura, Shigeru Fujita, Keiya Uriu, Jumpei Ito, and Kei Sato. 2022. ‘[Neutralisation Sensitivity of SARS-CoV-2 Omicron Subvariants to Therapeutic Monoclonal Antibodies](https://doi.org/10.1016/S1473-3099(22)00365-6)’. _The Lancet Infectious Diseases_.
* [PREPRINT] Young-Xu, Yinong, Lauren Epstein, Vincent C. Marconi, Victoria Davey, Gabrielle Zwain, Jeremy Smith, Caroline Korves, Fran Cunningham, Robert Bonomo, and Adit A. Ginde. 2022. ‘[Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data](https://doi.org/10.1101/2022.05.28.22275716)’. _medRxiv_.
* Loo, Yueh-Ming, Patrick M. McTamney, Rosalinda H. Arends, Michael E. Abram, Anastasia A. Aksyuk, Seme Diallo, Daniel J. Flores, et al. ‘[The SARS-CoV-2 Monoclonal Antibody Combination, AZD7442, Is Protective in Nonhuman Primates and Has an Extended Half-Life in Humans](https://doi.org/10.1126/scitranslmed.abl8124)’. _Science Translational Medicine_ 14, no. 635 (9 March 2022): eabl8124.

## Secondary References
This secondary bibliography presents a selection of references on topics not directly related to Evusheld but that are of interest (e.g. the mental health implications of shielding).

* Daniels, Jo, and Hannah Rettie. ‘[The Mental Health Impact of the COVID-19 Pandemic Second Wave on Shielders and Their Family Members](https://doi.org/10.3390/ijerph19127333)’. International Journal of Environmental Research and Public Health 19, no. 12 (January 2022): 7333.

## Events
* AstraZeneca. 2022. ‘[The Unmet Needs of Immunocompromised Patients Post-COVID 19](https://www.politico.eu/event/the-unmet-needs-of-immunocompromised-patients-post-covid-19/)’. _POLITICO_. 9 June 2022.

## Media

<iframe src="https://player.vimeo.com/video/719537557?h=78adcb4cb9" width="640" height="480" frameborder="0" allow="autoplay; fullscreen; picture-in-picture" allowfullscreen></iframe>
<p><a href="https://vimeo.com/719537557">BBC News - 3pm - 21 February 2022</a> from <a href="https://vimeo.com/shannonleebanks">Shannon Banks</a> on <a href="https://vimeo.com">Vimeo</a>.</p>